Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research

Tayla A. Rees*, Alejandro Labastida-Ramírez, Eloisa Rubio-Beltrán

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
105 Downloads (Pure)

Abstract

The neuropeptides calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) and their receptors are linked to migraine neurobiology. Recent antimigraine therapeutics targeting the signaling of these neuropeptides are effective; however, some patients respond suboptimally, indicating an incomplete understanding of migraine pathophysiology. The CGRP- and PACAP-responsive receptors can be differentially spliced. It is known that receptor splice variants can have different pathophysiological effects in other receptor-mediated pain pathways. Despite considerable knowledge on the structural and pharmacological differences of the CGRP- and PACAP-responsive receptor splice variants and their expression in migraine-relevant tissues, their role in migraine is rarely considered. Here we shine a spotlight on the calcitonin and PACAP (PAC1) receptor splice variants and examine what implications they may have for drug activity and design.

Original languageEnglish
Pages (from-to)651-663
Number of pages13
JournalTrends in Pharmacological Sciences
Volume44
Issue number10
Early online date3 Aug 2023
DOIs
Publication statusPublished - Oct 2023

Fingerprint

Dive into the research topics of 'Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research'. Together they form a unique fingerprint.

Cite this